ArticleBMC infectious diseases2025
Serum cytokine analysis in cavitary and non-cavitary pulmonary Mycobacterium avium complex disease: a cross-sectional study.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundIn pulmonary Mycobacterium avium complex (MAC) disease, serum cytokine profiles may offer insights into the immune responses underlying cavitary lesion development. We aimed to compare serum cytokine profiles between patients with cavitary and those with non-cavitary nodular bronchiectasis (NB) and to identify cytokines potentially associated with cavitary lung lesions.
methodsThis single-center, cross-sectional study included patients with pulmonary MAC disease presenting with NB, categorized into the cavitary and non-cavitary groups. The serum levels of 34 exploratory cytokines were measured using the MAGPIX system and enzyme-linked immunosorbent assays. Intergroup comparisons were subsequently performed.
resultsNine and 45 patients with cavitary and non-cavitary NB MAC, respectively, were included. Significantly higher levels of interleukin (IL)-6 and IL-8/C-X-C motif chemokine ligand 8 (inflammatory markers), matrix metalloproteinase-8 and chitinase-3-like protein 1 (tissue remodeling factors), and IL-17E/IL-25 and suppression of tumorigenicity 2/IL-33R (T-helper type 2-related cytokines) were observed in the cavitary group. No significant differences were identified for the remaining cytokines.
conclusionsCavitary lung lesions in pulmonary MAC disease are associated with elevated levels of inflammatory markers, tissue remodeling factors, and T-helper type 2 related cytokines. Future research should investigate whether these cytokine differences contribute to cavity formation or occur as a consequence, and explore their potential as therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.